Georgia's Online Cancer Information Center

Plasma cell neoplasm Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Plasma cell neoplasm
Cancer Type = Plasma cell neoplasm
There are currently 23 active Plasma cell neoplasm clinical trials in Georgia.
1.
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT04133636
Protocol IDs
CR108581
NCI-2019-07363
68284528MMY2003
2018-004124-10
3.
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
Cancer Type
Hematopoietic Malignancies, Multiple Myeloma, Plasma cell neoplasm, Unknown Primary
NCT ID
NCT04196491
Protocol IDs
BB2121-MM-004
NCI-2020-00209
U1111-1243-5088
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03601078
Protocol IDs
BB2121-MM-002
NCI-2018-01730
U1111-1216-4209
2018-000264-28
Treatment Sites (1)
5.
Battery Powered Drill versus Conventional Methods in Comparing Quality of Bone Marrow Biopsy, Convenience, and Pain Control in Patients with Plasma Cell Disorders
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03078452
Protocol IDs
Winship2656-14
NCI-2017-00308
IRB00075658
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6.
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients with High-Risk Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03756896
Protocol IDs
Winship4101-17
NCI-2017-02052
IRB00097882
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
7.
Collection and Storage of Tissue and Blood Samples from Patients with Cancer
Cancer Type
Lymphoma, Multiple Myeloma, Plasma cell neoplasm, Solid Tumor
NCT ID
NCT02474160
Protocol IDs
9846
9846
NCI-2015-00863
P9846
P9846_R02PAPPHOLD01
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
8.
Daratumumab, Ixazomib, and Dexamethasone with or without Bortezomib in Treating Patients with Newly Diagnosed Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03942224
Protocol IDs
Winship4547-18
NCI-2018-03615
IRB00102336
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
9.
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma with Kidney Failure
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT04352205
Protocol IDs
WINSHIP4949-20
NCI-2020-01133
NCI-2020-01133
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
10.
Denosumab in Treating Patients with Multiple Myeloma with Kidney Insufficiency
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT02833610
Protocol IDs
15-571
NCI-2016-01375
Treatment Sites (1)
11.
Depleted Immune Suppressor Stem Cell Transplant in Enhancing Immune Response to Vaccines in Patients with Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT02700841
Protocol IDs
WINSHIP2905-15
NCI-2015-00743
IRB00079982
12.
Influenza Vaccination in Preventing the Flu in Patients with Plasma Cell Disorders
Cancer Type
Plasma cell neoplasm
NCT ID
NCT04080531
Protocol IDs
Winship4709-19
NCI-2019-03734
IRB00111721
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
13.
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Cancer Type
Hematopoietic Malignancies, Plasma cell neoplasm, Unknown Primary
NCT ID
NCT04754945
Protocol IDs
Winship5086-20
NCI-2020-06548
14.
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
Cancer Type
Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm, Solid Tumor
NCT ID
NCT02840110
Protocol IDs
UT-201502
NCI-2017-00314
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
15.
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients with Multiple Myeloma
Cancer Type
Bone Tumor, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03858205
Protocol IDs
16M-18-2
NCI-2018-03600
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
16.
Melphalan before Stem Cell Transplant for the Treatment of Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT04483206
Protocol IDs
WINSHIP5001-20
NCI-2020-04920
STUDY00000449
17.
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Cancer Type
Bile Duct Cancer, Breast Cancer, Leukemia, Lung Cancer, Multiple Myeloma, Plasma cell neoplasm, Stomach/ Gastric Cancer, Unknown Primary, Uterine Cancer
NCT ID
NCT02393248
Protocol IDs
INCB 54828-101
NCI-2015-00611
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
18.
Rifaximin in Treating Patients with Monoclonal Gammopathy
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03820817
Protocol IDs
Winship4480-18
NCI-2018-02106
IRB00106380
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
19.
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
Cancer Type
Leukemia, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03486067
Protocol IDs
CC-93269-MM-001
NCI-2018-02280
2017-003448-19
U1111-1210-6325
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
20.
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type
Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm
NCT ID
NCT02693535
Protocol IDs
Pro00014171
NCI-2017-00510
Treatment Sites (2)
21.
NCORP Trial NCI Priority
Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type
Bladder Cancer, Brain & Spinal Cord Tumor, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Plasma cell neoplasm, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Thyroid Cancer, Unknown Primary, Uterine Cancer
NCT ID
NCT02465060
Protocol IDs
EAY131
NCI-2015-00054
EAY131-A
EAY131-B
EAY131-E
EAY131-F
EAY131-G
EAY131-H
EAY131-Q
EAY131-R
EAY131-U
EAY131-V
Treatment Sites (29)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Cancer Center at DeKalb Medical Center
Decatur
Cathy Comer
404-501-7789
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
22.
23.
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Plasma cell neoplasm
NCT ID
NCT03805789
Protocol IDs
CSL964_2001
NCI-2019-03310
2018-000329-29
Treatment Sites (1)
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.